Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Hepatic Carcinoma Clinical Trial

Official title:

Microwave Ablation Combined With Simultaneous TACE Plus Sintilimab for Unresectable HCC.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04220944
• Other study ID #: ZS-IR-2019B
• Status: Recruiting
• Phase: Phase 1
• Start date: January 1, 2020
• Est. completion date: September 30, 2022

Study information

• Verified date: September 2021
• Source: Shanghai Zhongshan Hospital
• Contact: zhiping Yan, MD
• Phone: +8613681971205
• Email: yan.zhiping[@]zs-hospital.sh.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.

Description:

Hepatocellular carcinoma is the most frequent primary and ranked as the sixth most common neoplasm and the third leading cause of cancer death. Percutaneous ablation and TACE are the effective locoregional treatments for the patient with HCC. Moreover, some studies suggested that TACE combined with ablation could further improve the survival rate and reduce the post-operation complication. Although PD-1 inhibitor was approved by FDA for HCC, the latest RCT indicated that no significant difference was found in the ORR and PFS between the groups of PD-1 inhibitor and Sorafenib. Therefore, this study aims to assess the efficacy and safety of microwave ablation combined with simultaneous TACE plus PD-1 inhibitor for the non-resectable HCC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: September 30, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age: 18 - 80 years old and life expectancy of at least 12 weeks.;

2. Clinically or histologically diagnosed as HCC and the diameter of target tumor lesion = 5 cm;

3. Child-pugh classification A or B (score < 7);

4. BCLC Staging as B or C;

5. ECOG 0-1;

6. Patients voluntarily entered the study and signed informed consent form (ICF).

Exclusion Criteria:

1. History of treatment with any local treatment (exception of liver transplantation), systemic .anti-cancer therapy, or immunotherapy;

2. The surgeon assessed that the tumor lesion was not unsuitable for microwave ablation;

3. Any contraindications for hepatic embolization procedures:

1. Known hepatofugal blood flow;

2. Total thrombosis of main portal vein.

4. The tumor thrombus of main portal vein, IVC or right atrium;

5. Tumor burden = 70% of liver volume; and no measurable site of disease as defined by modified RECIST (mRECIST) criteria with spiral CT scan or MRI;

6. Subjects with chronic HBV infection have HBV DNA viral load > 100 IU/mL at screening, and have not received antiviral therapy prior to initiation of study therapy; In addition, coinfection of HBV and HCV;

7. The alcoholic or pregnant women;

8. Patients with second primary cancer or history of other cancer within 3 years;

9. Diagnosis of active autoimmune disease, immunodeficiency, or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of Sintilimab-monotherapy treatment;

10. Blood count, liver function: Haemoglobin < 9.0 g/dL, white cell count < 1.0 x10^9/L; Total bilirubin > 3 mg/dL; Aspartate Aminotransferase (SGOT) or Alanine aminotransferase (SGPT) > 5 x upper normal limit (ULN), Albumin < 2.8g/dL; International normalized ratio (INR) >2.3;

11. Renal function dysfunction: Serum Creatinine >2 mg/dL or creatinine clearance (CrCl) < 30 mL/min (if using the Cockcroft-Gault formula ); and severe heart, lung, brain or other organ disease;

12. Non-compliance with TACE or ablation procedure.

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Hepatic Carcinoma

Intervention

Drug:
• Sintilimab
Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.

Procedure:
• Microwave Ablation
The ablation area should covered at least two thirds the size of the nodules.
• TACE
Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.

Locations

Country	Name	City	State
China	Department of Interventional Radiology, Zhongshan Hospital, Fudan University.	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital	Innovent Biologics (Suzhou) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS)	Progression according to mRECIST for HCC.	Observation period max 18 months
Secondary	Objective Response Rate (ORR)	Objective Response Rate according to mRECIST for HCC	max 18 months
Secondary	Time to Progression (TTP)	It is defined as the time from first locoregional therapy to the date of the first documented tumor progression according to the definition above.	max 18 months
Secondary	Overall survival (OS)	Overall survival is defined as the time from first locoregional therapy until death	max 18 months
Secondary	Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V5.0 (Safety and Tolerability)	Data will be obtained on vital signs, clinical parameters and feasibility of the regimen	max 18 months